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78436 | RSC Adv., 2016, 6, 78436–784t Ehm2/1 in breast cancer MCF-7
cells interacted with b-catenin and increased its
localization to plasma membrane†
Hefen Yu,abc Zhicheng Ge,bcde Yang Si,abc Gang Chen,abc Yuxiang Zhangabc
and Wen G. Jiang*abce
Ehm2, which belongs to the FERM superfamily, is a metastasis-associated protein. However, its function in
cancer metastasis and the associated molecular mechanism is not deﬁnitely clear. Alternative splicing is an
important biological step during mRNA processing and has been reported to be related with many diseases
including cancers. Ehm2 has two transcript variants. Transcript variant 1(Ehm2/1) encodes isoform 1 of 518
amino acids, while transcript variant 2(Ehm2/2) encodes isoform 2 of 913 amino acids. In this study, we
found that Ehm2/1 was the main transcript variant in the MCF-7 breast cancer cell line. Forced
expression of Ehm2/1 upregulated the total protein amount but had no eﬀect on the mRNA levels of b-
catenin. The increased b-catenin was found to be dominantly located at the cell membrane. Meanwhile,
knockdown of Ehm2/1 in MCF-7 cells decreased the total protein amount but not the mRNA levels of b-
catenin. Further results showed that Ehm2/1 interacted with b-catenin and colocalized with it at the cell
membrane. E-cadherin, a partner of b-catenin in cadherin-catenin complexes, was also upregulated by
the overexpression of Ehm2/1 and also colocalized with it at the cell membrane. Meanwhile,
overexpression of Ehm2/1 inhibited the migration ability of MCF-7 cells. These results suggested that
Ehm2/1 may render b-catenin at the cell membrane by interacting with b-catenin and E-cadherin.Introduction
Ehm2, also called erythrocyte membrane protein band 4.1-like
protein 4B (EPB41L4B), is expressed in highmetastatic cells and
belongs to the FERM (Four.1 protein, ezrin, radixin, moesin)
superfamily. Ehm2 has been suggested to be linked with cancer
metastasis by regulating interactions between cell surface
transmembrane proteins and cytoskeletal proteins.1,2 However,
the exact role of Ehm2 is not well known. Human Ehm2 was
shown to be androgen-regulated in a human brosarcoma cell
line model of steroid-regulated cytoskeletal reorganization.3
Wang et al. reported that the expression of the FGFR-4 Arg388
variant resulted in the increased expression of Ehm2 in prostate
epithelial cells.3,4 They also found that Ehm2 expression was
upregulated in prostate cancer cell lines and prostate cancerBiology, School of Basic Medicine, Capital
ina
ity, Beijing 100069, P. R. China
and Metastasis Research, Beijing 100069,
riendship Hospital Capital University of
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tion (ESI) available. See DOI:
44tissues. The enhanced expression of Ehm2 in prostate cancer
may promote disease progression and metastasis.4 In our
previous study, we showed that Ehm2 was highly expressed in
breast cancer, and its higher expression was correlated with
distant metastasis and poor patient prognosis.5 We also
demonstrated that the knockdown of Ehm2 induced apoptosis
potential and decreased the in vitro invasive properties of MCF-7
breast cancer cells by regulating the expression and activity of
matrix metalloproteinase 9.
Alternative splicing is an important biological step during
mRNA biosynthesis in eukaryotes and has been reported to be
related to many diseases including cancers.6–10 It is estimated
that 90% of all multi-exon genes are subjected to some form of
alternative splicing.11–13 Alternative splicing of a single gene can
give rise to functionally distinct protein isoforms.14–16 However,
very little is known about whether alternate transcripts are
a driving force or the result of cancer progression.
Chauhan et al. conducted tissue expression analysis of the
human Ehm2 gene and found that there were two Ehm2 protein
isoforms (isoform 1 and isoform 2).3,17 Isoform 2, which was
translated from Ehm2/2, contains 913 amino acids, whereas
isoform 1 exists ubiquitously in the testes, prostate and breast
and is produced from Ehm2/1. In comparison with isoform 2,
isoform 1 is missing 382 amino acids at the carboxyl terminal
region containing recognizable protein motifs.3 This may
suggest that Ehm2 isoform 1 function is a constitutively activeThis journal is © The Royal Society of Chemistry 2016
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View Article OnlineFERM signaling protein that is controlled by transcriptional
regulation rather than by autoregulation involving the intra-
molecular folding of subdomains.18,19 As mentioned above,
Ehm2 is a metastasis-associated protein in prostate cancer and
breast cancer; however, it is diﬃcult to discriminate which
transcript variant plays the dominant role in these processes.
Thus, understanding the functions of these transcript variants
is necessary to determine their potential roles in breast cancer.
We analyzed the levels of the transcript variants of Ehm2 in
breast cancer cell lines MCF-7 and MDA-MB-231. We found that
MCF-7 cells contained primarily the transcript variant 1 of
Ehm2, while MDA-MB-231 cells had both variants at relatively
high levels. Based on our previous result that the knockdown of
Ehm2 induced cell apoptosis and decreased the in vitro invasive
properties of MCF-7 cells,5 and that Ehm2/1 was dominantly
expressed MCF-7 cells, we speculated that Ehm2/1 may function
by regulating b-catenin in MCF-7 cells. In current study, we
forced the expression of Ehm2/1 in MCF-7 cells and found that
the upregulation of Ehm2/1 may render b-catenin at the cell
membrane by interacting with b-catenin and inhibiting the
migration ability of MCF-7 cells.
Materials and methods
Cell cultures
MCF-7, MDA MB-231 and A549 cells were purchased from the
ATCC. HEK-293A cell lines were gied by Professor Junqi He
from Capital Medical University. Cells were routinely cultured in
DMEMwith L-glutamine (Thermo Fisher Scientic Inc., Carlsbad,
USA) supplemented with streptomycin, penicillin (Ameresco,
Solon, USA) and 10% fetal bovine serum (ExCell Bio, Shanghai,
China) in an incubator at 37 C, 5% CO2 and 95% humidity.
Gene knockdown and overexpression
Knockdown of Ehm2 in MCF-7 cells was performed using trans-
fection with anti-human Ehm2 hammerhead ribozyme, which was
designed based on the secondary structure of Ehm2 transcript
variant 1 generated using Zuker's RNA mFold program20 and
cloned into a mammalian expression pEF6/V5-His-TOPO plasmid
vector (Thermo Fisher Scientic Inc, Carlsbad, USA). The stable
clones were established by treatment with blasticidine.
Express plasmid of Ehm2/1 (NM_018424.2) tagged with
FLAG was purchased from OriGene Technologies (Cat.
RC223085, Beijing, China). For overexpression of Ehm2/1, cells
were transfected with pCMV-entry and pCMV-Ehm2/1-FLAG.
Stable transfectants were selected with medium containing
500 mg ml1 G418.
For transfection, 1 mg of express vectors or ribozyme vectors
were mixed with 4 ml of Lipofectamine® 2000 Reagent (Thermo
Fisher Scientic Inc, Carlsbad, USA). Aer 20 min of complex
formation, the liposomes were given to the cells plated in six-
well plates for the analysis of gene expression.
RNA isolation and reverse transcription PCR
Total RNA was extracted from the cell lines with TRIzol Reagent
(Thermo Fisher Scientic Inc, Carlsbad, USA). Extracted RNAThis journal is © The Royal Society of Chemistry 2016was reverse transcribed into rst-strand cDNA using an
IScript™ cDNA Synthesis Kit (Bio-Rad, Hercules, USA). PCR was
carried out using a REDTaq™ ReadyMix PCR reaction mix
according to the manufacturer's instructions. The specic
primers were: Ehm2/1 forward, 50-CACTTTGAGAGACTGAAGCA-
TCTC-30 and reverse, 50-CAACTTCTACGACAGGAATATATGC-30;
Ehm2/2 forward, 50-CCTGTTGCGGATCATGTGAAGTG-30 and
reverse, 50-TATCAGGAAACGGGTTCATTGTATC-30; b-catenin
forward, 50-AGGGATTTTCTCAGTCCTTC-30 and reverse, 50-
GAACCAAGCATTTTCACCAG-30; CyclinD1 forward, 50-GAACA-
GAAGTGCGAGGAGGAG-30 and reverse, 50-AGGCGGTAGTAGGA-
CAGGAAG-30; GAPDH forward, 50-GGCTGCTTTTAACTCTGGTA-30
and reverse, 50-GACTGTGGTCATGAGTCCTT-30. Cycling condi-
tions were 94 C for 5 min followed by 30 cycles of 94 C for 30 s,
56 C for 30 s, and 72 C for 40 s. This was followed by a nal 10
min extension period at 72 C. The products were visualized on
1.2% agarose gel stained with ethidium bromide.
Immunoblotting and isolation of nuclear, cytosol and
membrane proteins
Cells were lysed in lysis buﬀer (20 mM Tris–HCl, pH 7.4, con-
taining 150 mM NaCl, 0.5% NP-40, 1.5 mM MgCl2, 1.5 mM
EGTA and 10% glycerol) containing complete protease inhibitor
cocktail (Roche Applied Science, Penzberg, Germany) for 30min
before clarication at 13 000  g for 20 min. Protein concen-
trations were determined using a BCA Protein Assay kit (Thermo
Fisher Scientic Inc, Carlsbad, USA) and an ELx800 spectro-
photometer (BioTek Instruments Inc, Burlington, USA). Equal
amounts of proteins were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE), and blotted
onto nitrocellulose sheets. Aer blocking for 1 h in 5% non-fat
dry milk in Tris-buﬀered saline, the membranes were incubated
overnight with the desired primary antibody. The membranes
were then treated with the appropriate HRP-conjugated
secondary antibody (115-035-044 and 111-035-003, Jackson
ImmunoResearch Inc, West Grove, USA). Protein bands were
visualized using Pierce ECL Plus Western Blotting Substrate
(Thermo Fisher Scientic Inc, Carlsbad, USA) and photo-
graphed using an LAS-3000 imager (FujiFilm, Tokyo, Japan).
The primary antibodies used to target b-catenin (ab22656), E-
cadherin (ab40772), Snail (ab167609) and LaminA/C (ab108595)
were from Abcam Ltd, (Cambridge, UK). Anti-b-actin (SC-
130301) and anti-Ehm2 antibodies (SC-14234) were from
Santa Cruz (San Diego, California, USA). Anti-FLAG antibody (F-
1804) was from Sigma-Aldrich Ltd. (Poole, UK).
Nuclear, cytosol and membrane proteins analyzed by
immunoblotting were isolated using the Nucl-Cyto-Mem Prep-
aration Kit (APPLYGEN, Beijing, China) according to the
manufacturer's instructions.
Immunoprecipitation and GST pull-down assay
For immunoprecipitation, the cells were lysed in lysis buﬀer (20
mM Tris–HCl, pH 7.4 containing 150 mMNaCl, 0.5% NP-40, 1.5
mM MgCl2, 1.5 mM EGTA and 10% glycerol) containing
complete protease inhibitor cocktail. Lysates (200 mg of total
protein) were incubated with 2 mg of Anti-FLAG antibodyRSC Adv., 2016, 6, 78436–78444 | 78437
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View Article Online(F-1804) overnight and then with 20 ml of protein A-agarose
beads (GE Healthcare, Chicago, USA) for 4 h at 4 C. b-Cat-
enin, E-cadherin and FLAG were detected by incubating the
blots with specic antibodies.
For GST pull-down assays, 293A cells transiently transfected
with pCMV-Ehm2/1-FLAG were lysed in lysis buﬀer (20 mM
Tris–HCl, pH 7.4 containing 150 mMNaCl, 0.5% NP-40, 1.5 mM
MgCl2, 1.5 mM EGTA and 10% glycerol) containing complete
protease inhibitor cocktail. b-Catenin-GST fusion proteins and
GST proteins (a gi from Dr He Junqi, Capital Medical Univer-
sity) and glutathione-Sepharose 4B beads (GE Healthcare, Chi-
cago, USA) were added to the lysate. Aer 4 h of incubation at 4
C, the beads were washed ve times in lysis buﬀer. The ob-
tained samples were analyzed by western blotting.Immunouorescence
Cells were xed with 3.7% formaldehyde in PBS for 10 min at
room temperature (RT). The xed cells were then per-
meabilized with 0.2% Triton X-100 in PBS for 10 min and
blocked with 2% BSA in PBS for 30 min at RT. Thereaer, the
cells were incubated with the appropriate primary antibodies
in 1% BSA in PBS with 0.2% Triton X-100 for 1.5 h at 37 C. The
primary antibody used to stain b-catenin (9581) was from Cell
Signaling Technology (Beverly, Massachusetts, USA). The
primary antibodies used to stain E-cadherin (ab40772) and
Ehm2/1 (ab77484) were from Abcam Ltd. (Cambridge, UK).
Anti-FLAG antibody (F-1804) was from Sigma-Aldrich Ltd.
(Poole, UK). Next, the cells were washed three times with PBS
and incubated with Alexa Fluor 488 donkey anti-mouse IgG
(1423052) or Alexa Fluor 594 donkey anti-rabbit IgG (1454437;
Thermo Fisher Scientic Inc., Carlsbad, USA) in 1% BSA in PBS
with 0.2% Triton X-100 for 1 h at RT. Aer three washes with
PBS, coverslips were incubated with DAPI for 5 min at RT. Aer
three washes with PBS and then rinsing in water (Milli-Q;
Millipore, Billerica, USA), the coverslips were mounted with
DAKO Fluorescent Mounting Medium (DAKO North America,
Inc., Carpinteria, USA). Spectral image acquisition was per-
formed using a Leica SP8 confocal microscope (Leica Micro-
systems, Wetzlar, Germany).Cell migration assay
Cell migrationwas assessed by wound-healing assay; 500 000 cells
were seeded into each well of a six-well plate and allowed to reach
near conuence. The layer of cells was then scraped with a ne-
gauge needle and washed once with phosphate buﬀered saline.
Themovement of cells to close the wound was recorded over time
using an Olympus phase-contrast microscope (Olympus, Tokyo,
Japan). Cell migration was evaluated with Image J.Fig. 1 Expression of endogenous Ehm2 and its subcellular distribu-
tion. (A) Ehm2 transcript variants in breast cancer cell lines were
diﬀerently expressed. RNA was extracted from cell lines. Reverse
transcription PCR was carried out using primers speciﬁc to Ehm2
transcript variants 1 and 2, and GAPDHwas used as internal control. (B)
Endogenous Ehm2/1 (green) was mainly distributed along the cell
membrane.Statistical analysis
Experimental procedures were repeated independently at least
three times. Data were expressed as mean  s.d., and statistical
comparisons were made using analysis of variance. Signicant
diﬀerences (p < 0.05) between the means of the two test groups
were analyzed by Student's t-test.78438 | RSC Adv., 2016, 6, 78436–78444Results
Ehm2 transcript variants were expressed diﬀerently in
diﬀerent breast cancer cells, and Ehm2/1 was distributed at
the cell membrane
To investigate the potential functions of Ehm2 transcript vari-
ants in breast cancer, we rst analyzed the expression patterns
of the two Ehm2 transcript variants in two breast cancer cell
lines. Ehm2/1 was expressed at moderate levels in both cell
lines, although its expression was much higher in MDA-MB-231
cells; in contrast, the expression of Ehm2/2 was high in MDA-
MB-231 cells but very low in MCF-7 cells (Fig. 1A). This result
indicates that both transcript variants of Ehm2 are expressed
diﬀerently and may have distinct roles in breast cancer
progression. The western blot results showed that only Ehm2/1
(about 58 kDa) was detected in MCF-7 cells (data not shown).
Cell immunouorescence using goat-anti-Ehm2 antibody was
carried out to detect the subcellular localization of endogenous
Ehm2/1; the results showed that endogenous Ehm2/1 was
mainly distributed at the cell membrane (Fig. 1B, ESI Fig. S1†),
although this antibody is poor for immunouorescence assay.
Changing the expression of Ehm2/1 in MCF-7 altered the
protein levels but had no eﬀect on the mRNA levels of b-
catenin
Considering that Ehm2 transcript 1 was moderately expressed
in MCF-7 cells, whereas the expression of Ehm2 transcript
variant 2 was very low, we focused on the role of Ehm2/1 in
MCF-7 cells. To study the role of Ehm2/1 in MCF-7 cells, we
developed an Ehm2/1-overexpressed MCF-7 cell line by trans-
fecting MCF-7 cells with pCMV-Ehm2/1-FLAG (MCF-7-Ehm2/
1ex) and Ehm2/1 knockdown MCF-7 cell lines using anti-Ehm2This journal is © The Royal Society of Chemistry 2016
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View Article Onlinehammerhead ribozyme transgenes (MCF-7-DEhm2/1). We veri-
ed the overexpression of Ehm2/1 using ordinary reverse-
transcription PCR and western blotting (Fig. 2A and C, ESI
Fig. S2†). The antibody used to detect Ehm2 was raised against
a peptide mapping within the internal region of Ehm2 so that it
could recognize Ehm2/1 and Ehm2/2. The results showed that
only Ehm2/1 was detected. We also conrmed that Ehm2
ribozyme transgenes successfully knocked down the expression
of Ehm2/1 within the MCF-7 cells (Fig. 2B and D).
In our previous study, we found that the knockdown of Ehm2
had inhibitory eﬀects on the in vitro growth and invasion of
MCF-7 cells and signicantly decreased the mRNA and protein
levels of MMP9 as well as its enzymatic activities.5 We hypoth-
esized that Ehm2 may cause these eﬀects by interacting with b-
catenin, a co-transcription factor in Wnt signaling.21,22 There-
fore, we assessed the expression of b-catenin in MCF-7-Ehm2/
1ex and MCF-7-DEhm2/1 cells. The overexpression of Ehm2/1 in
MCF-7 cells signicantly increased the protein levels of b-cat-
enin (p < 0.01, Fig. 2A and ESI Fig. S3†) but had no eﬀect on its
mRNA levels (Fig. 2C and ESI Fig. S4†). In contrast, the knock-
down of Ehm2/1 signicantly decreased the protein levels of b-
catenin (p < 0.05, Fig. 2B and ESI Fig. 3†) and also had no eﬀectFig. 2 Eﬀect of overexpression and knockdown of Ehm2/1 on endogen
nously expressed b-catenin protein levels. MCF-7 cells stably transfec
subjected to western blotting using anti-Ehm2 and anti-b-catenin antib
sitometrically quantiﬁed and normalized to the amounts of b-actin pres
pCMV-entry control (set to 1, right panel). (B) Knockdown of Ehm2/1 decre
transfected with pEF and Ehm2 ribozyme constructs were harvested an
antibodies (left panel). The immunoreactive bands of b-catenin were d
present in each sample and then averaged. Data shown are relative to the
unaﬀected by altering the expression of Ehm2/1. RNA was extracted from
out using primers speciﬁc to Ehm2/1 and b-catenin (left panel), and th
amounts of GAPDH and shown relative to the corresponding control (se
paired t-test in comparison to control; error bars indicate SD; * indicate
This journal is © The Royal Society of Chemistry 2016on its mRNA levels (Fig. 2D and ESI Fig. S4†). These results
showed that Ehm2/1 regulates the protein levels of b-catenin
through a mechanism other than transcription regulation.Ehm2/1 interacted with b-catenin
To understand the molecular mechanism by which Ehm2/1
upregulates the protein levels of b-catenin, we identied the
interaction of Ehm2/1 with b-catenin. First, the interaction
between FLAG-tagged Ehm2/1 and endogenous b-catenin was
detected by the overexpression of Ehm2/1 inMCF-7 cells and co-
immunoprecipitation assay (Fig. 3A). The results showed that
FLAG coprecipitated with b-catenin and veried the upregula-
tion of endogenously expressed b-catenin in the total lysate of
Ehm2/1 overexpressed MCF-7 cells. We conrmed the interac-
tion of Ehm2/1 with b-catenin by GST pull-down assays using
GST-fused b-catenin in HEK-293A cells transiently transfected
with pCMV-Ehm2/1-FLAG (Fig. 3B). Cell immunouorescence
showed that Ehm2/1 detected using tagged-FLAG antibody was
mainly localized at the cell membrane and colocalized with b-
catenin (Fig. 3C). These results indicated that Ehm2/1 can
interact with b-catenin at the cell membrane.ous b-catenin. (A) Overexpression of Ehm2/1 increased the endoge-
ted with pCMV-entry and pCMV-Ehm2/1-FLAG were harvested and
odies (left panel). The immunoreactive bands of b-catenin were den-
ent in each sample and then averaged. Data shown are relative to the
ased the endogenously expressed b-catenin protein levels. Cells stably
d subjected to western blotting using anti-Ehm2 and anti-b-catenin
ensitometrically quantiﬁed and normalized to the amounts of b-actin
pEF control (set to 1, right panel). (C, D) mRNA levels of b-catenin were
the same cell lines as in A and B. Reverse transcription PCR was carried
e intensities were densitometrically quantiﬁed and normalized to the
t to 1, right panel). Note: n ¼ 3; statistical signiﬁcance was assessed by
s signiﬁcance at p < 0.05; ** indicates signiﬁcance at p < 0.01.
RSC Adv., 2016, 6, 78436–78444 | 78439
Fig. 3 Ehm2 interacted with b-catenin. (A) Lysates of MCF-7 cells stably transfected with pCMV-entry or pCMV-Ehm2/1-FLAG constructs were
immunoprecipitated (IP) with anti-FLAG antibody. (top) Total lysate and coprecipitated b-catenin were detected by immunoblotting with anti-b-
catenin antibody. (middle) Total lysate and IP FLAG were detected with immunoblotting. (bottom) Comparable amounts of b-actin were
expressed as loading control. (B) Lysates of HEK-293A cells transfected with pCMV-Ehm2/1-FLAG were examined for GST pull-down assays
using GST or b-catenin-GST. Ehm2/1 was detected by immunoblotting with anti-FLAG antibody. Comparable amounts of GST and b-catenin-
GST beads were used by staining themembrane using ponceau S. (C) In MCF-7 cells expressing Ehm2/1-FLAG, the Ehm2/1-FLAG staining (green)
signiﬁcantly overlaps with that of b-catenin (red) along the cell membrane.
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View Article OnlineOverexpression of Ehm2/1 increased the fraction of
membraneous b-catenin but not cellular and nuclear b-
catenin
b-Catenin is a critical component of cadherin-based adhesion
junctions and also a regulatory node of the Wnt signaling
pathway.23 The result that Ehm2/1 interacted with b-catenin at
the cell membrane prompted us to investigate the subcellular
localization of b-catenin upon Ehm2/1 upregulation. We iso-
lated the cell-membrane, cytosolic and nuclear fractions and
detected the level of b-catenin in each fraction. The results
showed that Ehm2/1 upregulation signicantly increased the
levels of b-catenin in the cell-membrane fraction (p < 0.05) and
had no obvious eﬀects on the cytosolic and nuclear b-catenin
fractions (Fig. 4A), which promotes the transcription of target
genes including cyclin D1 and c-myc.24–26 In fact, the over-
expression of Ehm2/1 in MCF-7 did not increase the mRNA78440 | RSC Adv., 2016, 6, 78436–78444levels of cyclin D1, a downstream target gene of b-catenin
(Fig. 4B), indicating that the nuclear localization of b-catenin
was not aﬀected by the overexpression of Ehm2/1. This result
indicated that Ehm2/1 may render b-catenin at the cell
membrane.Overexpression of Ehm2/1 increased the protein levels of E-
cadherin and inhibited cell migration
Cell membrane-localized b-catenin is a member of the E-
cadherin/catenin complex, which forms adhesion junctions.
To determine if Ehm2/1 regulates cadherin-catenin complexa-
tion, we analyzed the protein levels of E-cadherin and the
colocalization of Ehm2/1 with E-cadherin in MCF-7-Ehm2/1ex
cells. E-cadherin was signicantly upregulated in MCF-7-Ehm2/
1ex cells compared to in control cells (p < 0.05, Fig. 5A). Cell
immunouorescence showed that Ehm2/1 mainly distributedThis journal is © The Royal Society of Chemistry 2016
Fig. 4 Overexpression of Ehm2/1 elevated cell-membrane localization of b-catenin. (A) Overexpression of Ehm2/1 increased b-catenin levels in
the cell-membrane fraction. Cells stably transfected with pCMV-entry and pCMV-Ehm2/1-FLAG were harvested and fractioned with a kit to
isolate cell-membrane, cytosolic and nuclear proteins, and b-catenin was then analyzed using western blotting. GAPDHwas the loading control
of cytoplasmic proteins, and LaminA/C was used as a loading control for nuclear proteins. Along with GAPDH and LaminA/C, b-actin, a loading
control for entire cell proteins, was also used as a loading control for cell membrane (left panel). The immunoreactive bands of b-catenin were
densitometrically quantiﬁed and normalized to the amounts of b-actin present in each sample and then averaged (right panel). (B) Cyclin D1,
a target gene of b-catenin, was unaﬀected at the transcription level by the overexpression of Ehm2/1. RNA isolated from cells stably transfected
with pCMV-entry, and pCMV-Ehm2/1-FLAGwas reverse transcripted into cDNA. ThemRNA levels of cyclin D1were then detected using ordinary
RT-PCR (left panel), and the intensities were densitometrically quantiﬁed and normalized to the amounts of GAPDH and shown relative to the
pCMV-entry control (set to 1, right panel). Note: n ¼ 3; statistical signiﬁcance was assessed by paired t-test in comparison to the control; error
bars indicate SD; * indicates signiﬁcance at p < 0.05.
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View Article Onlineat the cell membrane and colocalized with E-cadherin (Fig. 5B).
Adhesion junctions were associated with cell migration; there-
fore, we analyzed the migration ability of MCF-7-Ehm2/1ex cells
using wounding assay. The results showed that the upregula-
tion of Ehm2/1 caused an obvious decrease in cell migration,
although the tendency was not signicant (Fig. 5C, p > 0.05).
This result was in line with the increasing distribution of b-
catenin at the cell membrane. In fact, the upregulation of
Ehm2/1 not only decreased cell migration, but also reduced the
invasion ability of MCF-7 cells (p < 0.05, ESI Fig. S5†).Discussion
Ehm2/1 is generated by transcript variant 1, which lacks several
exons and includes an alternate 30 terminal exon compared to
variant 2. Thus, Ehm2/1 is shorter and has a distinct C-terminus
compared to Ehm2/2. The biological functions of Ehm2/1 and
Ehm2/2 are not denitively known. In the present study, we
found that MCF-7 cells mainly express Ehm2/1, which is
a membrane-associated protein. One of the main ndings ofThis journal is © The Royal Society of Chemistry 2016this study is that Ehm2/1 interacts with b-catenin and retards it
at the cell membrane. Membranous b-catenin is a critical
component of cadherin-based cell–cell adhesion. Our results
also conrmed that Ehm2/1 interacts with E-cadherin at the cell
membrane and upregulates its protein levels.
Ehm2 is a FERM domain-containing protein and was origi-
nally identied as a metastasis-promoting protein in murine
melanoma cells.2 FERM domain-containing proteins have
conserved FERM domains, which mediate protein–protein
interactions.27–31 FERM domains can mediate intermolecular
interactions, usually by interacting with the cytoplasmic tails of
transmembrane proteins.18,32,33 For example, the ERM proteins
bind via their FERM domains to the cytoplasmic domains of
transmembrane proteins such as CD44.18 Murine Ehm2, also
called Lulu2, is a potent activator of cortical myosin II
contractile forces in epithelial cells.34Murine Ehm2 can interact
with p114RhoGEF through its FERMdomain and be recruited at
cell–cell boundaries.35 The Drosopholia orthologue of Ehm2,
called Yurt, was reported to be a negative regulator of apical
membrane size in epithelial cells.36 Yurt was recruited to theRSC Adv., 2016, 6, 78436–78444 | 78441
Fig. 5 Eﬀects of Ehm2/1 upregulation on endogenous E-cadherin and cell migration. (A) Overexpression of Ehm2/1 increased the endogenously
expressed E-cadherin protein levels. Cells stably transfected with pCMV-entry and pCMV-Ehm2/1-FLAG were harvested and subjected to
western blotting using anti-E-cadherin antibodies (left panel), and the intensities of E-cadhesion bands were densitometrically quantiﬁed and
normalized to the amounts of GAPDH and shown relative to the pCMV-entry control (set to 1, right panel). Note: n¼ 3; statistical signiﬁcancewas
assessed by paired t-test in comparison to the control; error bars indicate SD; * indicates signiﬁcance at p < 0.05. (B) In MCF-7 cells expressing
Ehm2/1-FLAG, the Ehm2/1-FLAG staining (green) signiﬁcantly overlaps with that of E-cadherin (red) along the cell membrane. (C) Ehm2/1
upregulation reduced cell migration compared with the pCMV-entry group, although the diﬀerence was not signiﬁcant. Shown are represen-
tative results of three independent experiments of wounding assay. Quantiﬁcation of migrated space is shown in the right graph (n¼ 3; error bars
indicate SD).
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View Article Onlineapical membrane by Crb and can bind directly to the FDB site in
the cytoplasmic tail of Crb through its FERM domain.37 Zebra-
sh Moe, the sole Ehm2 molecule in the species, participates in
the layering of the retina and ination of the brain ventricles as
well as restricting the photoreceptor apical domain.38 Moe also
interacts with and negatively regulates Crumbs, thereby
restricting apical membrane size in epithelial structures.39
Mammalian EPB41L5, a FERM protein very similar to Ehm2
(EPB41L4B), associates with the intracellular domains of
Crumbs through its FERM domain and is involved in main-
taining cell polarity.40 Like its orthologues in other species and
homology in mammals, human endogenous Ehm2 was78442 | RSC Adv., 2016, 6, 78436–78444distributed at the cell membrane in this study. Considering that
Ehm2/1 is not highly expressed in MCF-7 cells, and Ehm2
antibody is not quite right for cell immunouorescence, human
lung adenocarcinoma epithelial A549 cells were used for
endogenous distribution assay. Exogenous overexpressed Ehm2
was also distributed at the cell membrane.
b-Catenin is a critical component of cadherin-based cell–cell
adhesion and also a regulatory node of the Wnt signaling
pathway.41 It links cadherins indirectly to the actin cytoskel-
eton.42,43 It also interacts with the LEF/TCF family members of
transcriptional activators as a critical intermediate in Wnt
signal transduction pathways.24,44–47 In this study, we found thatThis journal is © The Royal Society of Chemistry 2016
Paper RSC Advances
Pu
bl
ish
ed
 o
n 
27
 Ju
ly
 2
01
6.
 D
ow
nl
oa
de
d 
by
 C
ar
di
ff 
U
ni
ve
rs
ity
 L
ib
ra
rie
s o
n 
10
/0
4/
20
17
 1
3:
21
:0
2.
 
View Article Onlineb-catenin can be regulated by Ehm2/1 and retained at the cell
membrane via interacting with Ehm2/1. The supporting
evidence was as follows: (i) in extracts of transfected MCF-7
cells, FLAG-tagged Ehm2/1 co-immunoprecipitated b-catenin;
(ii) b-catenin pulled down FLAG-tagged Ehm2/1 in extracts of
the transfected 293A cells; and (iii) FLAG-tagged Ehm2/1 co-
localized with b-catenin at the cell membrane. These results
were consistent with the role of 4.1R, the prototypical member
of the protein 4.1 superfamily, in linking the cadherin/catenin
complex to the cytoskeleton through its direct interaction with
b-catenin.48,49 Therefore, we speculated that the FERM domain
of Ehm2/1 behaves similarly to those of the 4.1 and ERM
proteins. However, we cannot be sure whether the interaction of
Ehm2/1 with b-catenin is direct or indirect. EPB41L5 can bind to
the C-terminal armadillo repeat region of p120ctn through its
N-terminal FERM domain.50 In future work, we will analyze the
structural basis of the interaction between Ehm2/1 and b-cat-
enin to verify the binding of the N-terminal FERM domain of
Ehm2/1 to the armadillo repeat region of b-catenin. Further-
more, we cannot exclude the possibility of indirect interaction
between Ehm2/1 and b-catenin. In fact, Ehm2/1 also co-
localized with E-cadherin at cell–cell contacts. Ehm2/1 has the
potential to indirectly interact with b-catenin through binding
to E-cadherin. Ezrin, forming a subfamily of conserved proteins
in the band 4.1 superfamily with radixin, moesin and merlin,
regulates cell–cell and cell-matrix adhesion by interacting with
the cell-adhesion molecules E-cadherin and b-catenin.51 Cad-
herin–catenin complexes at adherens junctions can decrease
cell migration and cell invasion. In our study, we found that
MCF-7 cells overexpressing Ehm2/1 showed decreased cell
migration, although the diﬀerence was not statistically signi-
cant. We speculate that the reason for the lack of statistical
signicant was that the basal E-cadherin and b-catenin levels
were quite high in MCF-7 cells. Our results showed that the
upregulation of Ehm2/1 indeed reduced the invasion ability of
MCF-7 cells signicantly (p < 0.05). Considering the important
role of Ehm2/1 in regulating cell migration and invasion
through the b-catenin-E cadherin axis, we speculated that
Ehm2/1 has negative regulation in EMT. Our nding that the
overexpression of Ehm2/1 decreased the protein levels of the
EMT marker Snail further conrmed our hypothesis (ESI
Fig. S6†). However, how Ehm2/1 is connected to E-cadherin at
the molecular level and how Ehm2/1 regulates EMT remain to
be elucidated.
In summary, we demonstrated that Ehm2/1 is the principal
Ehm2 protein in MCF-7 cells and is a regulator of the cadherin–
catenin complexes. Elucidating the more detailed mechanisms
of the Ehm2/1-cadherin–catenin system is a future important
challenge to understand the role of Ehm2.Acknowledgements
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